Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
22 results
  • Lymphoma

22-555          Phase II

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies

  • Lung Cancer, Bladder Cancer, Kidney Cancer, Lymphoma, Melanoma

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma

  • Lung Cancer, Melanoma, Lymphoma, Head and Neck Cancer

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

  • Lymphoma

20-404          Phase II

A multicenter phase 2 study of belantamab mafodotin in relapsed or refractory plasmablastic lymphoma and ALK+ large B-cell lymphoma

  • Lymphoma

20-508          Phase I

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

  • Lymphoma, Multiple Myeloma

21-245          Phase II

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma

  • Lymphoma

23-177          Phase II

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome

  • Lymphoma

22-149          Phase II

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Lymphoma, Cellular Therapy

21-422          Phase II

A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas

  • Lymphoma

19-743          Phase II

A Phase 2 Study of MRD Adapted Therapy with Venetoclax-Obinutuzumab in Patients with High or Intermediate Risk Relapsed or Refractory CLL, with Addition of Acalabrutinib in Patients who Fail to Achieve MRD Eradication

Showing 1 - 10 of 22 results